Cytosorbents (CTSO) Hisse Özeti
Cytosorbents Corporation, Amerika Birleşik Devletleri, Almanya ve uluslararası alanda kan saflaştırma teknolojisi platformu ile tıbbi cihazların araştırılması, geliştirilmesi ve ticarileştirilmesi faaliyetlerini yürütmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 1/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
CTSO Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cytosorbents Corporation Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$0.36 |
| 52 Haftanın En Yüksek Seviyesi | US$1.30 |
| 52 Haftanın En Düşük Seviyesi | US$0.36 |
| Beta | 1.36 |
| 1 Aylık Değişim | -26.26% |
| 3 Aylık Değişim | -35.35% |
| 1 Yıllık Değişim | -70.57% |
| 3 Yıllık Değişim | -89.92% |
| 5 Yıllık Değişim | -95.07% |
| Halka arzdan bu yana değişim | -99.17% |
Son Haberler & Güncellemeler
CTSO: Nasdaq Extension And Clinical Data Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Cytosorbents from $10.00 to $5.00, citing updated assumptions that now reflect a higher discount rate, more moderate revenue growth expectations, slightly lower profit margin forecasts, and a modestly lower future P/E multiple. What's in the News Nasdaq granted Cytosorbents a 180 day extension, until September 28, 2026, to regain compliance with the minimum US$1.00 bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2).
CTSO: Nasdaq Compliance Extension Will Support Future Turnaround Potential
Analysts have reduced their fair value estimate for Cytosorbents from $5.00 to $2.88 as they recalibrate assumptions for revenue growth, profit margins, the discount rate, and the stock's future P/E multiple. What's in the News On April 1, 2026, Cytosorbents received a 180 day extension from Nasdaq until September 28, 2026 to regain compliance with the minimum US$1.00 bid price requirement for continued listing.Recent updates
CTSO: Nasdaq Extension And Clinical Data Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Cytosorbents from $10.00 to $5.00, citing updated assumptions that now reflect a higher discount rate, more moderate revenue growth expectations, slightly lower profit margin forecasts, and a modestly lower future P/E multiple. What's in the News Nasdaq granted Cytosorbents a 180 day extension, until September 28, 2026, to regain compliance with the minimum US$1.00 bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2).CTSO: Nasdaq Compliance Extension Will Support Future Turnaround Potential
Analysts have reduced their fair value estimate for Cytosorbents from $5.00 to $2.88 as they recalibrate assumptions for revenue growth, profit margins, the discount rate, and the stock's future P/E multiple. What's in the News On April 1, 2026, Cytosorbents received a 180 day extension from Nasdaq until September 28, 2026 to regain compliance with the minimum US$1.00 bid price requirement for continued listing.
CTSO: ICU Utilization And Nasdaq Compliance Extension Will Support Future Upside
Analysts have kept the fair value estimate for Cytosorbents steady at $0.75. Modest tweaks to assumptions for the discount rate, revenue growth, profit margin, and future P/E reflect updated views on risk, earnings power, and likely valuation multiples.CTSO: ICU Adoption And Nasdaq Compliance Efforts Will Support Future Upside
Analysts have maintained their $0.75 price target on Cytosorbents. They cite small adjustments in the discount rate, revenue growth assumptions, and future P/E estimates as they refine their models, while keeping their overall valuation view unchanged.CTSO: 2025 Revenue Outlook And ICU Adoption Will Support Upside
Analysts have maintained their $0.75 price target for Cytosorbents, citing only modest adjustments to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock’s valuation. What's in the News Nasdaq granted CytoSorbents a 180 day extension, until September 28, 2026, to regain compliance with the US$1.00 minimum bid price requirement for continued listing on the exchange, with the stock remaining listed during this period (Delistings notice).CTSO: Steady 2025 Outlook And ICU Therapy Progress Will Support Upside
Analysts have held their fair value estimate for Cytosorbents steady, keeping the implied price target unchanged at $0.75. This reflects slightly adjusted views on discount rate, revenue growth and profit margin assumptions, without a clear shift in overall conviction.CTSO: Steady 2025 Revenue Guidance Will Support Measured Long Term Upside
Analysts have made a modest adjustment to their Cytosorbents price target, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Taken together, these changes leave their fair value estimate broadly unchanged around $0.75.CTSO: Flat 2025 Outlook And Cost Discipline Will Support Measured Upside
Analysts have slightly adjusted their price target for Cytosorbents to reflect updated assumptions around revenue growth, profit margin and future P/E, while keeping the fair value broadly in line at $0.75. What's in the News Cytosorbents issued earnings guidance for the fourth quarter of 2025, with revenue expected to be approximately US$9.2 million, the same figure as guidance for the fourth quarter of 2024 (Key Developments).CTSO: Cost Cuts And 2026 Cash Flow Break Even Will Support Upside
Analysts have trimmed their price target on Cytosorbents to reflect a slightly lower assumed discount rate, marginally higher projected revenue growth, improved profit margin expectations, and a modestly lower future P/E multiple. This results in a revised valuation that they see as better aligned with updated assumptions.CTSO: Cost Cuts And 2026 Cash Flow Break Even Will Shape Outlook
Narrative Update on Cytosorbents Analysts have kept their price target for Cytosorbents steady at US$0.75, citing updated assumptions that reflect slightly lower discount rates, modestly higher projected revenue growth, a stable profit margin outlook, and a small adjustment to expected future P/E levels. What's in the News Cytosorbents issued earnings guidance for the fourth quarter of 2025, with revenue expected to be approximately US$9.2 million, in line with the fourth quarter of 2024 at US$9.2 million (Key Developments).CTSO: Cost Reductions And 2026 Cash Flow Break Even Will Support Upside
Analysts have updated their price target on Cytosorbents and maintained fair value at US$0.75. They have also fine tuned underlying assumptions such as the discount rate, revenue growth, profit margin and future P/E to reflect revised views on the company’s risk and earnings profile.CTSO: Cost Cuts And Nasdaq Listing Risk Will Shape Balanced Outlook
Analysts modestly raised their price target on Cytosorbents to reflect a slightly lower discount rate and higher expected future earnings multiples, even as they tempered long term revenue growth assumptions. What's in the News Cytosorbents announced a strategic workforce and cost reduction plan, cutting approximately 10% of its staff and realigning production and operating expenses to target operating cash flow break even by the first quarter of 2026 (Key Developments).CTSO: Workforce Cuts And FDA Pathway Are Expected To Shape Outlook
Analysts have trimmed their price target on Cytosorbents from approximately 12.84 dollars to 7.96 dollars. This reflects slightly lower long term revenue growth assumptions, a higher perceived risk profile, and only modestly improved profitability expectations.Market Cool On Cytosorbents Corporation's (NASDAQ:CTSO) Revenues Pushing Shares 31% Lower
To the annoyance of some shareholders, Cytosorbents Corporation ( NASDAQ:CTSO ) shares are down a considerable 31% in...Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...FDA And Health Canada Approval Will Spur ICU Solutions
Cytosorbents’ consensus price target has been raised from $5.00 to $7.00, reflecting improved profitability with net profit margin rising to 12.34% and a more attractive future P/E of 74.11x. What's in the News New studies demonstrate early and intensive CytoSorb® therapy significantly improves clinical outcomes for sepsis and septic shock patients, with peer-reviewed data showing increased survival rates when used intensively and early.Does Cytosorbents (NASDAQ:CTSO) Have A Healthy Balance Sheet?
NasdaqCM:CTSO 1 Year Share Price vs Fair Value Explore Cytosorbents's Fair Values from the Community and select yours...Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 54% Bounce
Cytosorbents Corporation ( NASDAQ:CTSO ) shareholders would be excited to see that the share price has had a great...
FDA And Health Canada Decisions Will Advance DrugSorb-ATR Launch
Regulatory decisions on DrugSorb-ATR could drive significant revenue growth, especially in the U.S. and Canada, with a large market opportunity.Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 28% Bounce
Cytosorbents Corporation ( NASDAQ:CTSO ) shareholders are no doubt pleased to see that the share price has bounced 28...The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More
Despite an already strong run, Cytosorbents Corporation ( NASDAQ:CTSO ) shares have been powering on, with a gain of...Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)
With a price-to-sales (or "P/S") ratio of 1.3x Cytosorbents Corporation ( NASDAQ:CTSO ) may be sending bullish signals...Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper
Unfortunately for some shareholders, the Cytosorbents Corporation ( NASDAQ:CTSO ) share price has dived 28% in the last...Hissedar Getirileri
| CTSO | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | -17.4% | 3.9% | -2.5% |
| 1Y | -70.6% | -19.9% | 19.0% |
Getiri vs. Endüstri: CTSO geçen yıl % -19.9 oranında getiri sağlayan US Medical Equipment sektörünün gerisinde kaldı.
Getiri vs Piyasa: CTSO geçen yıl % 19 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| CTSO volatility | |
|---|---|
| CTSO Average Weekly Movement | 12.8% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: CTSO hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: CTSO 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1997 | 129 | Phil Chan | www.cytosorbents.com |
Cytosorbents Corporation, Amerika Birleşik Devletleri, Almanya ve uluslararası alanda kan saflaştırma teknolojisi platformu ile tıbbi cihazların araştırılması, geliştirilmesi ve ticarileştirilmesi faaliyetlerini yürütmektedir. Amiral gemisi ürünü CytoSorb, yaygın kritik hastalıklarda sitokin fırtınalarını, karaciğer yetmezliğinde bilirubini, travma ve kritik hastalıklarda miyoglobini ve kalp cerrahisi uygulamalarında enflamatuar mediatörleri ve kan incelticileri azaltmanın yanı sıra kardiyotorasik cerrahi uygulamalarında antitrombotik ilaçları ve enflamatuar mediatörleri gidermek için ekstrakorporeal bir kan saflaştırma kartuşudur. Şirket ayrıca, kan inceltici ilaçlar nedeniyle yüksek riskli cerrahide perioperatif kanamanın şiddetini azaltmak için bir araştırma cihazı olan DrugSorb-ATR antitrombotik uzaklaştırma sistemini; ex vivo organ perfüzyon sisteminde kullanıldığında sitokinleri ve diğer enflamatuar aracıları azaltmak için ECOS-300CY'yi geliştirmektedir; Hayvanlarda septik şok, toksik şok sendromu, toksin aracılı hastalıklar, pankreatit, travma, karaciğer yetmezliği, sıcak çarpması ve akciğer hasarının tedavisi için geniş spektrumlu bir kan saflaştırma adsorberi olan VetResQ; ve kan saflaştırma tedavileri için gelişmiş bir hemoperfüzyon pompası olan PuriFi.
Cytosorbents Corporation Temel Bilgiler Özeti
| CTSO temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$22.73m |
| Kazançlar(TTM) | -US$11.85m |
| Gelir(TTM) | US$37.20m |
CTSO aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| CTSO gelir tablosu (TTM) | |
|---|---|
| Gelir | US$37.20m |
| Gelir Maliyeti | US$10.79m |
| Brüt Kâr | US$26.41m |
| Diğer Giderler | US$38.26m |
| Kazançlar | -US$11.85m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.19 |
| Brüt Marj | 71.01% |
| Net Kâr Marjı | -31.85% |
| Borç/Özkaynak Oranı | 773.0% |
CTSO uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/28 16:00 |
| Gün Sonu Hisse Fiyatı | 2026/06/26 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Cytosorbents Corporation 6 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Sean Lee | H.C. Wainwright & Co. |
| Anthony Petrone | Jefferies LLC |